No Data
No Data
Shanghai Microport Endovascular Medtech(Group) Co., Ltd. (688016.SH): plans to implement mid-term dividend in 2024.
On July 10th, Gelunhui reported that Shanghai Microport Endovascular Medtech (Group) Co., Ltd. (688016.SH) plans to implement a mid-year dividend in 2024 based on the actual situation and future development needs of the company. If there are distributable profits in the first half of 2024, the mid-year dividend in 2024 will not be less than 50% of the net income attributable to the shareholders of the listed company in the first half of 2024.
MicroPort Scientific Forecasts Decline in Net Loss for H1 on Higher Revenue
MicroPort Scientific (HKG:0853) forecasts a "significant" decline in its net loss for the six months ended June 30 due to a 17% rise in revenue, according to a Monday filing with the Hong Kong Stock
Shanghai MicroPort Endovascular MedTech (SHSE:688016) Is Reinvesting At Lower Rates Of Return
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Amongst other things, we'll want to see two things; firstly, a growing return on
MicroPort Endovascular Expects Up to 30% Profit Growth in H1; Shares Rise 6%
Shanghai MicroPort Endovascular MedTech (SHA:688016) expects its net profit attributable to the equity owners for the six months ended June 30 to be in the range of 777.0 million yuan and 808.1 millio
Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd.: Voluntary disclosure announcement of the 2024 semi-annual performance forecast.
Selected announcements from geloncize: shanghai microport endovascular medtech(group)co.,ltd. expects net income to increase by 40% to 50% year-on-year in the first half of the year; cofco biotechnology plans to invest 185 million yuan to expand its Cheng
Investment project: Cofco Biotechnology (000930.SZ): plans to invest 185 million yuan to expand Chengdu company's annual production of 150,000 tons of starch sugar projects. Cofco Biotechnology (000930.SZ) announced that in order to improve the industrial layout of starch sugar business, enhance market share, and improve market competitiveness, the company plans to invest in expanding the COFCO Biochemical (Chengdu) Co., Ltd.'s 150,000 tons/year starch sugar project. The total investment is approximately 185,261.3 million yuan (the final total investment of the project is subject to actual investment). The construction period is 18 months from the date of project approval to successful commissioning. Contract Award: Hongrun Construction Group (00206
No Data